DYNE THERAPEUTICS INC (DYN) Stock Price, Quote, News and Overview
NASDAQ:DYN - Nasdaq - US26818M1080 - Common Stock - Currency: USD
DYN Quote, Performance and Key Statistics
11.69
-0.21 (-1.76%)
The current stock price of DYN is 11.69 USD. In the past month the price increased by 5.7%. In the past year, price decreased by -62.56%.
DYN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 323.71B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6.17 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About DYN
Company Profile
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 191 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Company Info
DYNE THERAPEUTICS INC
1560 Trapelo Road
Waltham MASSACHUSETTS 02451 US
CEO: Joshua Brumm
Employees: 191
Phone: 17817868230
DYNE THERAPEUTICS INC / DYN FAQ
What is the stock price of DYNE THERAPEUTICS INC today?
The current stock price of DYN is 11.69 USD. The price decreased by -1.76% in the last trading session.
What is the ticker symbol for DYNE THERAPEUTICS INC stock?
The exchange symbol of DYNE THERAPEUTICS INC is DYN and it is listed on the Nasdaq exchange.
On which exchange is DYN stock listed?
DYN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DYNE THERAPEUTICS INC stock?
18 analysts have analysed DYN and the average price target is 51.63 USD. This implies a price increase of 341.64% is expected in the next year compared to the current price of 11.69. Check the DYNE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DYNE THERAPEUTICS INC worth?
DYNE THERAPEUTICS INC (DYN) has a market capitalization of 1.33B USD. This makes DYN a Small Cap stock.
How many employees does DYNE THERAPEUTICS INC have?
DYNE THERAPEUTICS INC (DYN) currently has 191 employees.
What are the support and resistance levels for DYNE THERAPEUTICS INC (DYN) stock?
DYNE THERAPEUTICS INC (DYN) has a support level at 11.68 and a resistance level at 11.78. Check the full technical report for a detailed analysis of DYN support and resistance levels.
Should I buy DYNE THERAPEUTICS INC (DYN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DYN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DYN, evaluating the profitability, health, valuation and growth aspects
- DYNE THERAPEUTICS INC (DYN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DYNE THERAPEUTICS INC (DYN) Sales and EPS estimates to see what analysts future expectations are.
- DYNE THERAPEUTICS INC (DYN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DYNE THERAPEUTICS INC (DYN) Insider and Institutional Ownership to learn about the owners and their transactions.
- DYNE THERAPEUTICS INC (DYN) Stock Chart to make your own analysis
- DYNE THERAPEUTICS INC (DYN) Latest news and press-releases to stay up to date.
Does DYNE THERAPEUTICS INC (DYN) stock pay dividends?
DYN does not pay a dividend.
When does DYNE THERAPEUTICS INC (DYN) report earnings?
DYNE THERAPEUTICS INC (DYN) will report earnings on 2025-08-11, after the market close.
What is the Price/Earnings (PE) ratio of DYNE THERAPEUTICS INC (DYN)?
DYNE THERAPEUTICS INC (DYN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.59).
What is the Short Interest ratio of DYNE THERAPEUTICS INC (DYN) stock?
The outstanding short interest for DYNE THERAPEUTICS INC (DYN) is 13.4% of its float. Check the ownership tab for more information on the DYN short interest.
DYN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DYN. When comparing the yearly performance of all stocks, DYN is a bad performer in the overall market: 90.58% of all stocks are doing better.
DYN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DYN. No worries on liquidiy or solvency for DYN as it has an excellent financial health rating, but there are worries on the profitability.
DYN Financial Highlights
Over the last trailing twelve months DYN reported a non-GAAP Earnings per Share(EPS) of -3.59. The EPS increased by 9.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.92% | ||
| ROE | -50.4% | ||
| Debt/Equity | 0 |
DYN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to DYN. The Buy consensus is the average rating of analysts ratings from 18 analysts.